Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | carboplatin plus docetaxel | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, RNAi etc. |
| Sample | cell line (3AO) |
| Expression Pattern | down-regulated |
| Function Description | Among six up-regulating lncRNAs, we screened out carboplatin-docetaxel-induced lncRNA PVT1 which may be a central downstream target of carboplatin plus docetaxel because expression of PVT1 positively correlates with anticancer action of carboplatin plus docetaxel. Besides, p53 and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) were mediated by lncRNA PVT1, which may explain partially the anticancer activity of lncRNA PVT1. knockdown of lncRNA PVT1 cause a marked reduction in tumor size in a human ovarian cancer xenograft model. |
| Pubmed ID | 26097562 |
| Year | 2015 |
| Title | Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |